en ENGLISH
eISSN: 2299-8284
ISSN: 1233-9989
Nursing Problems / Problemy Pielęgniarstwa
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
3/2023
vol. 31
 
Poleć ten artykuł:
Udostępnij:
Artykuł oryginalny

Clients’ satisfaction with pain management by healthcare providers during sickle cell crisis in selected health facilities in Ogun State Nigeria – a cross sectional study

Funmilola A. Faremi
1
,
Bolanle A. Onitiju
2
,
Oluwayemisi E. Olagunju
1
,
Matthew I. Olatubi
3

  1. Nursing Science, Obafemi Awolowo University, Ile-Ife, Nigeria
  2. Clinical Nursing, State Hospital Ijaye, Nigeria
  3. Nursing Science, Bowen University, Iwo, Nigeria
Nursing Problems 2023; 31 (3): 140-147
Data publikacji online: 2023/12/06
Plik artykułu:
- Clients satisfaction.pdf  [0.64 MB]
Pobierz cytowanie
 
Metryki PlumX:
 

INTRODUCTION

Sickle cell disease (SCD) is a haemolytic anaemia associated with significant level of morbidity and mortality among the global populace. Sickle cell anaemia (HbSS) is the most austere form, while SC haemoglobinopathy (HbSC) is understood to be milder [1-4]. Al-Jafar described SCD as a congenital blood disorder inhibiting the normal functioning of haemoglobin [5]. The gene frequency of SCD is highest in West African countries, with 25-30% of people being carriers of HbS compared to 1 in 400 African Americans, and it is variable in European populations [6]. Severe morbidity and mortality ensue when SCD is not diagnosed and treated promptly [7]. In Nigeria, the overall prevalence of the 2 common variances of SCD are HbSS (2.14%) and HbSC (0.14%) [8].
It is one of the most common inherited life-threatening disorders in humans that predominantly affects people of African, Indian, and Arab ancestry [9, 10]. Despite increase awareness about the disease, a number of people in Nigeria are still not aware of their genotype to effectively prevent the disease [11]. This had led to increased prevalence of SCD. Similarly, the prevalence of SCD in developed countries is increasing, partly due to migration from high-prevalence countries [12, 13]. It is estimated that over 14,000 people live with SCD in the UK, similar to France, while countries like Italy and Germany have seen increasing numbers of people living with SCD from Africa [14-16]. These have made SCD a global challenge needing urgent attention.
In African countries where comprehensive medical care is not readily available, mortality as a result of SCD in early childhood is common. The hallmark of SCD across all ages is pain [3, 17], mostly termed as vaso-occlusive crisis (VOC) [7]. The most commonly experienced symptoms of SCD include fatigue, bone aches, difficulty concentrating, difficulty gaining weight, and joint stiffness, with varying levels of severity [18-21]. Apart from VOC, scholars have documented fatigue as the most common symptom of SCD [19], resulting is reduced functioning, school/work absenteeism, and lower quality of life [22-25].
The effective management of pain goes a long way in preserving the patients and aiding an improving quality of life. The management of pain rests majorly in the purview of healthcare professionals, caregivers and likewise the patients. The effectiveness of the methods of care utilized in the management of pain has been under-studied, hence there is dearth of literature in this regard.
Telfer et al. reported that despite advances in the healthcare management of acute pain in SCD patients, a significant level of dissatisfaction still exists [26]. This was shown to be strongly associated with the naïve methods of pain management using opioid analgesics [27, 28]. The discrepancy between patients’ report of satisfaction and reports of moderate to severe pain intensity could be related to the satisfaction measure used. In nearly all of the studies identified, the authors measured satisfaction at a global level: satisfaction with pain treatment [29], satisfaction with pain management [30], and satisfaction with care [31]. Despite the value of these measures of satisfaction, the items are too global and not sufficiently specific. When patients answer these global questions, they take into account several confounding factors, including communication with clinicians and time to receipt of pain medication, which may not relate to their pain intensity [32].
This study therefore seeks to provide insights into prevailing pain management strategies adopted in the care of SCD vaso-occlusive crisis, the satisfaction of patients with these identified strategies, and correlates of pain severity and pain management strategies.

MATERIAL AND METHODS

STUDY DESIGN AND SETTING
This study used a descriptive, cross-sectional design to investigate satisfaction with pain management during sickle cell crisis among clients attending sickle cell clinics in selected health facilities in Abeokuta, Ogun State.
Clients living with sickle cell disease, who were above 18 years old and attending the sickle cell clinics at 2 selected hospitals in Abeokuta, Ogun State participated in the study.
PARTICIPANTS
Participants were recruited using multi-stage sampling technique. Only clients who meet the inclusion criteria of having been diagnosed of SCD for at least one year and had been admitted to the hospital for at least 24 hours as result of an SCD crisis were recruited into the study.
VARIABLES AND MEASUREMENTS
The research instrument used for this study was a questionnaire. The questionnaire was divided into 4 sections covering the scope of the study. The first section assessed the socio-demographic characteristics of the participants in the study, while the second part comprised 5 items on a scale of 0-10 to assess participants’ pain levels. Participants were asked to rate their level of pain on the scale in the last week, 24 hours, and at the time of data collection. A score of 0 meant no pain at all, while 10 meant the worst pain possible. The level of pain was further graded into “No Pain” (0); “Mild Pain” (1-3); “Moderate Pain” (4-6); and “Severe Pain” (7-10) [33-35].
The third section of the questionnaire is an 8-item Likert scale that assessed methods of pain management. Participants were asked which of the pain management strategies is/are adopted in their management and the frequency of use of such strategies.
The last section assessed satisfaction with pain management methods and is made up of 19 items on a 5-point Likert scale. The mean score was used to categorise the into low and high levels of satisfaction with pain management.
The questionnaire was presented to a panel of experts for critiquing to ensure face validity and content validity. This was done to affirm that the instrument was adequate and appropriate for the study. The questionnaire was approved after all necessary modification were made. The questionnaire has a Cronbach alpha Coefficient score of 0.87. The questionnaire was therefore adjudged reliable.
Data collection was done by the researchers, with trained research assistants to help if participants were illiterate and were unable to read and fill out the questionnaire. The participants were met on hospital clinic days after obtaining permission from the hospital administrators. A research assistant was attached to each facility. The questionnaire was administered during the clinic support group meeting with the clients.
SAMPLE SIZE
The sample size for the study was obtained using the Cochran formula [36] for assessing sample sizes for descriptive studies:
Zcrit2pq
N = ––––––,
e2
where Z is the standard normal variance, the confidence level is 1.96 at 95%, p is the prevalence of SCD over the 5-year period under study (21.6%) [37], q = 1 – p, and d is the absolute precision or error margin tolerated, chosen as 5% (0.05).
1.962 (0.216) (1 – 0.216)
N = ––––––––––––––––––––– = 260
0.052
To correct for the finite population, discover in the clinic to be used, which was found to be an average of 150 sickle cell patients duly registered for each clinic, a correction formula by Cochran was further adopted:
n0
n = –––––––––
1 + n0 – 1
N ,
where n is the sample size, and N is the population size (150) [36].
260
n = ––––––––––– = 95
1 + 260 – 1
150
With a non-response rate of 20%, the sample size becomes 114.
STATISTICAL ANALYSIS
There was instant review of collected data to avoid omissions and correct any missed data before the participant left. Furthermore, data cleaning was done before the entry into statistical application software (SPSS 21.0), with which the data analysis was performed. Data were analysed using descriptive (frequency, mean, and standard deviation) and ANOVA inferential statistics.
ETHICAL CONSIDERATIONS
The study was approved by the Research and Ethics Committee of Ogun State Hospitals Management Board and Federal Medical Centre, Abeokuta. Participation was made optional, and all participants voluntarily consented to be part of the study. Collected data were stored and handled with utmost confidentiality.

RESULTS

Table 1 shows the socio-demographic characteristics of the participants. The gender distribution of the participants revealed that there were more female participants in the study (53.5%). The majority the participants were below 30 years of age, and only 7 (6.1%) participants were above 30 years of age. The genotypic information of the participants revealed that the majority (86.0%) had the HBSS gene while 14.0% had the HBSC gene. Pain levels among the participants in the study showed that 36.8% experienced pain in the last week, 33.3% in the last 24 hours, while only 13.2% experienced pain at the time of data collection (Figure 1). The result further showed that in the week prior the study, 63.2% reported no pain while 20.3% indicated a very mild level of pain. Also, 12.3% experienced moderate level of pain while 5 (4.5%) of the participants experienced a severe level of pain during the period. When asked to give a 24-hour pain assessment recall prior to the time of data collection, 66.7% indicated that they had no pain and about 28.1% had mild pain, and those that experienced moderate and severe levels of pain were 3.6% and 1.8%, respectively. At the point of data collection, the vast majority (86.8%) of the participants were not experiencing any pain. Some of the participants (11.5%) were experiencing a mild level of pain while only few (1.8%) were experiencing a moderate level of pain (Table 2).
A little less than half (46.5%) of the participants believed that their pain was localized in a particular part of their body. On the other hand, 34.2% believed that their pain referred to a different part of their body (Figure 1). Most of the participants describe the presence of burning (60.5%), tingling (58.8%), and sharp (54.4%) pain sensation. On the other hand, half of the participants described the presence of intense and lacerating pain. 48.2% described the presence of numbing pain. About 4 in every 10 participants in this study described the experience of excruciating (45.6%), piercing (43.9%), and horrible (41.2%) pain (Table 3).
Participants’ descriptions of their pain, as shown in Table 3, revealed that 27.2% said they had a mild tingling pain and 17.5% reported severe tingling pain. Furthermore, 27.2% had mild burning pain and 9.7% had a severe burning pain. Among the participants, 13.2% reported that they had a severe numbing experience, 12.3% experienced a severe lacerating pain, and 14.0% had severe intense pain. Also, 29.8% had mild inflammation, 27.2% had mild sharp pain, and 13.2% experienced severe sharp pain.
The result showed that 66.7% of the participants indicated that a comprehensive assessment is always done at presentation in the hospital (Table 4). 54.4% of the participants stated that pain-relieving drugs were always administered by the care providers within 30 minutes of arrival, while 21.9% reported that it was only done sometimes. 7.0% said opioids (codeine or morphine) were always given during their experience of persistent pain. Furthermore, 38.6% said they always received intravenous (IV) administration of pain-relieving drugs, while 29.8% received it sometimes.
Table 5 shows the assessment of effectiveness of method and medication route of pain management.
Half of the participants (50.0%) always received emotional support and counselling by the healthcare providers, while 27.2% said they were sometimes provided with non-pharmacological approaches, such as distraction, massage, muscle relaxation, and positioning. The assessment of the medication used by participant as presented in Table 6 showed that the oral route was the most common route of analgesic administration (82.5%). Also, 44.2% of the participant had an after-taste of the oral medication. However, 65.8% of the participants in this study opined that IM/IV pain medication worked quickly for them compared to oral drugs.
The findings from this study showed that the majority of the patients who participated (85.1%) were satisfied with the information received about their pain and its treatment. Also, the majority (73.7%) of the participants were satisfied with the care provided by the nurses for pain and the treatment of the pain. There was no statistically significant relationship between the level of pain experienced by the participants and the pain management strategies adopted (F(2,111) = 0.591, p = 0.556). Also, there was no statistically significant relationship between the level of satisfaction of the participants and the pain management strategies adopted (F(2,111) = 0.485, p = 0.617) (Tables 7 and 8).

DISCUSSION

There were more female participants than males. This is similar to a recent study conducted by Abdo et al. [38] among adolescent and paediatric patients, which recorded more female participants, and likewise the findings of Elander et al. [39]. The modal age range was 18-20 years. This represents the most active period of life, i.e. adolescence and youth. The clinical characteristic results showed that a larger proportion of the participants had an HbSS blood group while a few had SC. This result agrees with the previous findings that there are more people with HbSS genotype compared to HbSC [3, 38, 40]. This gender distribution revealed that an equal proportion of participants by gender had HbSS; however, more females than males had HbSC.
The study assessed the pain experience of the participants at different time periods prior the study. The findings showed that the majority rated their pain experience to be zero within the last 6 months prior to the study. An above average proportion of participants had tingling and burning pain. This is characteristic of neuropathic pain. Previous scholars documented the possibility neuropathic pain in patients with SCD [41-43]. This level is higher than in previous studies among adult patients with SCD [42, 44]. Other sensory pain experienced by participants was less than average.
Evaluation of the level of pain experienced by the participants showed that the majority experienced mild pain, while a few participants had severe pain. This result was not in agreement with the report of Abdo et al., in which most participants experienced severe to moderate pain, which could be attributed to the lack of self-care knowledge that could have helped in alleviating pain [38]. The reason for the low proportion of participants in this study with moderate/sever pain compared to the study by Abdo et al. study might be that while their study was conducted among SCD patients in a secondary/tertiary level hospital, ours was conducted among patients attending a primary level of health care [38]. Usually, primary level health care involves uncomplicated simple cases, while complicated ones are referred to secondary/tertiary level health care facilities.
The study investigated the pain management strategies used in alleviating the pain of the participants. It was found that a comprehensive examination was carried out on the patients before administration of any management method. Furthermore, most participants’ pain was addressed via a pharmacological approach, while few adopted both pharmacological and non-pharmacological approaches. Despite the documented advantages of the use of non-pharmacological strategies in the management of pain [17, 45], only few participants said it was adopted in their management. This study finding was similar to the findings of Abdo et al., where pain was mainly managed via pharmacological approach [38]. Suggested guidelines for management of SCD pain include the use of opioid and non-opioid medications in addition to non-pharmacological approaches [46-48]. It is therefore important to assess whether it is the lack of knowledge about non-pharmacological methods of pain management on the part of the health professional that results in the low use of the approach [49].
There was higher utilization of non-opioid medications than opioids in this study. This might be connected with the addictive nature of opioids, thereby discouraging their use in the management of SCD [27, 28]. The use of opioids was lower in this study when compared with the use as reported in earlier studies [38, 50]. This further confirms the poor management of pain in low- and middle-income countries like Nigeria [51]. Opioids are generally recommended in the acute management of SCD [7] but seldom used in Nigeria, which is evident from the findings of this study.
There was no significant relationship between the pain management strategies and the level of pain experienced by SCD patients in this study. Most participants were satisfied with pain management strategies delivered to them by the healthcare providers. This was further confirmed because the majority were satisfied with the level of information received about their pain and treatment [52]. The finding of the study revealed that participants reported that the doctors and nurses spent quality time with the patients.
Sickle cell disease patients need rapid assessment and pain management within 30 minutes of admission to the hospital, as well as reassessment following analgesic administration every 15 minutes until total pain relief. The impact of a nursing care service on the management of patients in a SCD is very important and necessary, to follow-up the patient and give an adequate explanation of proper usage of medications, analgesic of pain, hydroxyurea dose, folic acid, and regular immunization injections. These practices are associated with improved results and therefore lead to a decrease in the frequency of episodes of SCD and increased health care outcomes [47].

LIMITATIONS

The main limitation to this study is that it focuses on satisfaction with pharmacological and non-pharmacological approaches to manage SCD patients’ experience and perception of pain, whereas there are other personal issues like nutrition, quality of life, etc. that can influence individuals’ perception of pain.

CONCLUSIONS

The findings of the study showed a high level of satisfaction among the participants with the administered pain management strategies. There is generally low utilization of non-pharmacological strategies in the management of pain among the participants. Therefore, adoption of more non-pharmacological strategies to combat pain during crises can be a great advantage to patients with SCD.
Disclosure
The authors declare no conflict of interest.
References
1. Brewin JN, Rooks H, Gardner K, et al. Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). Haematologica 2021; 106: 1770-1773.
2. Brewin JN, Nardo-Marino A, Stuart-Smith S, et al. The pleiotropic effects of α-thalassemia on HbSS and HbSC sickle cell disease: reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival. Am J Hematol 2022; 97: 1275-1285.
3. Mobark NA, Alharbi M, Alhabeeb L, et al. Sickle cell disease: a distinction of two most frequent genotypes (HbSS and HbSC). PLoS One 2020; 15: e0228399.
4. Serjeant GR. Phenotypic variation in sickle cell disease: the role of beta globin haplotype, alpha thalassemia, and fetal hemoglobin in HbSS. Expert Rev Hematol 2022; 15: 107-116.
5. Al-Jafar H. Non-conventional pain management for sickle cell disease. Ann Hematol Oncol 2017; 4: 1161.
6. Aguilar Martinez P, Angastiniotis M, Eleftheriou A, et al. Haemoglobinopathies in Europe: health & migration policy perspectives. Orphanet J Rare Dis 2022; 9: 97.
7. Almuqamam M, Diaz-Frias J, Malik M, et al. Emergency management of SCD pain crises: current practices and playing variables. Pediatr Hematol Oncol J 2018; 3: 37-41.
8. Kingsley A, Enang O, Essien O, et al. Prevalence of sickle cell disease and other haemoglobin variants in Calabar, Cross River State, Nigeria. Annu Res Rev Biol 2019; 33: 1-6.
9. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115: 4331-4336.
10. Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 2011; 41: S398-S405.
11. Faremi AF, Olatubi MI, Lawal YR. Knowledge of sickle cell disease and premarital genotype screening among students of a tertiary educational institution in South Western Nigeria. Int J Caring Sci 2018; 11: 285-295.
12. Cela E, Bellón JM, de la Cruz M, et al. National registry of hemoglobinopathies in Spain (REPHem). Pediatr Blood Cancer 2017; 64.
13. Inusa BDP, Colombatti R. Pediatric blood & cancer European migration crises: the role of national hemoglobinopathy registries in improving patient access to care. Pediatr Blood Cancer 2017; 64: e26515.
14. Dormandy E, James J, Inusa B, et al. How many people have sickle cell disease in the UK? J Public Health 2018; 40: e291-e295.
15. Lobitz S, Telfer P, Cela E, et al. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. Br J Haematol 2018; 183: 648-660.
16. Colombatti R, Cela E, Elion J, et al. Editorial for special issue “Newborn screening for sickle cell disease and other haemoglobinopathies”. Int J Neonatal Screen 2019; 5: 5-6.
17. Lakkakula BVKS, Sahoo R, Verma H, et al. Pain management issues as part of the comprehensive care of patients with sickle cell disease. Pain Manag Nurs 2018; 19: 558-572.
18. Osunkwo I, Andemariam B, Inusa BP, et al. Impact of Sickle cell disease symptoms on patients’ daily lives: interim results from the International Sickle Cell World Assessment Survey (SWAY). Blood 2019; 134 (Suppl. 1): 2297.
19. Osunkwo I, Andemariam B, Minniti CP, et al. Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY). Am J Hematol 2021; 96: 404-417.
20. Khamees I, Ata F, Choudry H, et al. Manifestations of HbSE sickle cell disease: a systematic review. J Transl Med 2021; 19: 262.
21. AlRyalat SA, Nawaiseh M, Aladwan B, et al. Ocular manifestations of sickle cell disease: signs, symptoms and complications. Ophthalmic Epidemiol 2020; 27: 259-264.
22. Kambasu DM, Rujumba J, Lekuya HM, et al. Health-related quality of life of adolescents with sickle cell disease in sub-Saharan Africa: a cross-sectional study. BMC Hematol 2019; 19: 9.
23. Badawy SM, Beg U, Liem RI, et al. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv 2021; 5: 570-583.
24. Colombatti R, Casale M, Russo G. Disease burden and quality of life of in children with sickle cell disease in Italy: time to be considered a priority. Ital J Pediatr 2021; 47: 163.
25. Faremi FA, Olawatosin OA. Quality of life of adolescents living with sickle cell anaemia in Ondo State, Nigeria. Pan Afr Med J 2020; 35: 124.
26. Telfer P, Bahal N, Lo A, et al. Management of the acute painful crisis in sickle cell disease – a re-evaluation of the use of opioids in adult patients. Br J Haematol 2014; 166: 157-164.
27. Nnachi OC, Akpa CO, Nwani FO, et al. Pentazocine misuse among sickle cell disease patients and the role of lack of enforcement of opioid dispensing regulations by community pharmacies: a descriptive observational study. Adv Public Heal 2022; 2022: 3877882.
28. Akaba K, Ibanga I, Oshatuyi O, et al. Case report: successful management of opioid abuse and addiction in a known SCD patient at the University of Calabar Teaching Hospital, Calabar, Nigeria. Int J Res Reports Hematol 2018; 1: 23-27.
29. Dworkin RH, Jensen MP, Gould E, et al. Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. J Pain 2011; 12: 416-424.
30. Carrougher GJ, Ptacek JT, Sharar SR, et al. Comparison of patient satisfaction and self-reports of pain in adult burn-injured patients. J Burn Care Rehabil 2003; 24: 1-8.
31. Aisiku IP, Penberthy LT, Smith WR, et al. Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PISCES study. J Natl Med Assoc 2007; 99: 886-890.
32. Ezenwa MO, Molokie RE, Wang ZJ, et al. Satisfied or not satisfied: pain experiences of patients with sickle cell disease. J Adv Nurs 2016; 72 :1398-1408.
33. Childs J, Piva S, Fritz J. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine 2005; 30: 1331-1334.
34. Rodriguez C. Pain measurement in the elderly: a review. Pain Manag Nurs 2001; 2: 38-46.
35. Jensen M, McFarland C. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain 1992; 55: 195-203.
36. Cochran WG. Sampling Techniques. 2nd ed. John Wiley and Sons, Inc., New York 1963; 75.
37. Olagunju OE, Faremi FA, Olaifa O. Prevalence and burden of sickle cell disease among Undergraduates of Obafemi Awolowo University, Ile-Ife. J Community Med Prim Health Care 2017; 29: 74-80.
38. Abdo S, Nuseir KQ, Altarifi AA, et al. Management of sickle cell disease pain among adolescent and pediatric patients. Brain Sci 2019; 9: 182.
39. Elander J, Bij D, Kapadi R, et al. Development and validation of the Satisfaction with Treatment for Pain Questionnaire (STPQ) among patients with sickle cell disease. Br J Haematol 2019; 187: 105-116.
40. Brewin JN, Rooks H, Gardner K, et al. Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). Haematologica 2021; 106: 1770.
41. Orhurhu MS, Chu R, Claus L, et al. Neuropathic pain and sickle cell disease: a review of pharmacologic management. Curr Pain Headache Reports 2020; 24: 52.
42. Bartlett R, Ramsay Z, Ali A, et al. Health-related quality of life and neuropathic pain in sickle cell disease in Jamaica. Disabil Health J 2021; 14: 101107.
43. Sharma D, Brandow AM. Neuropathic pain in individuals with sickle cell disease. Neurosci Lett 2020; 714: 134445.
44. Signorelli AAF, Ribeiro SBF, Moraes-Souza H, et al. Pain measurement as part of primary healthcare of adult patients with sickle cell disease. Rev Bras Hematol Hemoter 2013; 35: 272-277.
45. Mahmood LA, Reece-Stremtan S, Idiokitas R, et al. Acupuncture for pain management in children with sickle cell disease. Complement Ther Med 2020; 49: 102287.
46. Mousa SA, Momen A, Sayegh F, et al. Review: management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost 2010; 16: 365-376.
47. Srouji R, Ratnapalan S, Schneeweiss S. Pain in children: assessment and nonpharmacological management. Int J Pediatr 2010; 2010: 474838.
48. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012; 120: 3647-3656.
49. Alotaibi K, Higgins I, Day J, et al. Paediatric pain management: knowledge, attitudes, barriers and facilitators among nurses – integrative review. Int Nurs Rev 2018; 65: 524-533.
50. Han J, Zhou J, Saraf SL, et al. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf 2018; 27: 479-486.
51. Morriss WW, Roques CJ. Pain management in low- and middle-income countries learning objectives. BJA Educ 2018; 18: 265-270.
52. Baskin J, Nord A, Canada D, et al. Utilization, trust and satisfaction with health care in adult sickle cell disease patients. Authorea 2020. DOI: 10.22541/au.159551282.29323158.
This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
© 2024 Termedia Sp. z o.o.
Developed by Bentus.